Telangiectasis: Clinical Trials

8 trials for Telangiectasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 8
Phase 21Completed 1

Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluate the Neurological Effects of EryDex on Subjects With A-T
Dexamethasone sodium phosphate, Placebo - Ataxia Telangiectasia
Phase 3CompletedQuince Therapeutics S.p.A.1052024-06-242026-04-30
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis
Phase 2 / Phase 3CompletedCure HHT712023-05-082026-10-27
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
Bevacizumab, sodium chloride 0.9% - Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
Phase 3CompletedHospices Civils de Lyon242017-09-282025-08-06
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
tranexamic acid - Telangiectasia, Hereditary Hemorrhagic, Osler-Rendu Disease
Phase 3CompletedHospices Civils de Lyon1702006-09-012019-05-28
Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)
Conjugated pneumococcal vaccine (Prevenar) - Ataxia Telangiectasia (AT)
Phase 3CompletedInstitute of Child Health302006-06-012008-04-11
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) - Retina, Telangiectasis
Phase 3CompletedUniversity of Sao Paulo312006-01-012008-07-23
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Tranexamic acid first, than placebo, First placebo, than Tranexamic acid. - Hereditary Hemorrhagic Telangiectasia
Phase 3CompletedUniversity Hospital, Saarland232002-03-012009-12-15
Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia
soy protein isolate - Hereditary Hemorrhagic Telangiectasia
Phase 3CompletedNational Center for Research Resources (NCRR)601996-01-012005-06-24

Narrower conditions

Telangiectasia, Hereditary Hemorrhagic (5)  ·  Epistaxis (3)  ·  Anemia (2)  ·  Ataxia Telangiectasia (2)  ·  Disease (1)  ·  Genetic Diseases, Inborn (1)  ·  Hematologic Diseases (1)  ·  Rare Diseases (1)  ·  Retinal Neovascularization (1)

Broader conditions

Cardiovascular Diseases (8)  ·  Vascular Diseases (8)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Cardiovascular Abnormalities (5)  ·  Congenital Abnormalities (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Hemorrhagic Disorders (5)  ·  Hemostatic Disorders (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Vascular Malformations (5)  ·  Hematologic Diseases (4)  ·  Hemorrhage (3)  ·  Nose Diseases (3)

Interventions

Bevacizumab (1)  ·  Cellulose (1)  ·  Heptavalent Pneumococcal Conjugate Vaccine (1)  ·  Sodium Chloride (1)  ·  Soybean Proteins (1)  ·  Tranexamic Acid (1)  ·  dexamethasone 21-phosphate (1)  ·  pazopanib (1)

Sponsors

Hospices Civils de Lyon (2)  ·  Cure HHT (1)  ·  Institute of Child Health (1)  ·  National Center for Research Resources (NCRR) (1)  ·  Quince Therapeutics S.p.A. (1)  ·  University Hospital, Saarland (1)  ·  University of Sao Paulo (1)

Countries

France (2)  ·  Germany (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Brazil (1)  ·  Denmark (1)  ·  Italy (1)  ·  Norway (1)  ·  Poland (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Dirk Thye, MD (1)  ·  James Gossage, MD (1)  ·  Joshua R. Korzenik (1)  ·  Otacilio O Maia Jr, M.D. (1)  ·  Urban W Geisthoff, Priv.-Doz. Dr.med. (1)  ·  Walter Y Takahashi, M.D. (1)

Results publications

PMID 17659962, PMID 25005464, PMID 25040799, PMID 30191360, PMID 37592715, PMID 42600624

NIH funding

2017 (1)